New Insights on End-Stage Renal Disease and Healthy Individual Gut Bacterial Translocation: Different Carbon Composition of Lipopolysaccharides and Different Impact on Monocyte Inflammatory Response

• Published in: Frontiers in immunology 2021-06, Vol.12, p.658404-658404
• Main Authors: Adda-Rezig, Hanane, Carron, Clémence, Pais de Barros, Jean-Paul, Choubley, Hélène, Charron, Émilie, Rérole, Anne-Laure, Laheurte, Caroline, Louvat, Pascale, Gaiffe, Émilie, Simula-Faivre, Dominique, Deckert, Valérie, Lagrost, Laurent, Saas, Philippe, Ducloux, Didier, Bamoulid, Jamal
• Format: Article
• Language: English
• Subjects: chronic inflammation; end-stage renal disease; gut bacterial translocation; HDL - cholesterol; Immunology; lipid A (LPS)
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.658404

Chronic kidney disease induces disruption of the intestinal epithelial barrier, leading to gut bacterial translocation. Here, we appreciated bacterial translocation by analyzing circulating lipopolysaccharides (LPS) using two methods, one measuring only active free LPS, and the other quantifying total LPS as well as LPS lipid A carbon chain length. This was done in end-stage renal disease (ESRD) patients and healthy volunteers (HV). We observed both higher LPS concentration in healthy volunteers and significant differences in composition of translocated LPS based on lipid A carbon chain length. Lower LPS activity to mass ratio and higher concentration of high-density lipoproteins were found in HV, suggesting a better plasma capacity to neutralize LPS activity. Higher serum concentrations of soluble CD14 and pro-inflammatory cytokines in ESRD patients confirmed this hypothesis. To further explore whether chronic inflammation in ESRD patients could be more related to LPS composition rather than its quantity, we tested the effect of HV and patient sera on cytokine secretion in monocyte cultures. Sera with predominance of 14-carbon chain lipid A-LPS induced higher secretion of pro-inflammatory cytokines than those with predominance of 18-carbon chain lipid A-LPS. TLR4 or LPS antagonists decreased LPS-induced cytokine production by monocytes, demonstrating an LPS-specific effect. Thereby, septic inflammation observed in ESRD patients may be not related to higher bacterial translocation, but to reduced LPS neutralization capacity and differences in translocated LPS subtypes.